Rifat Pamukcu is Director of Aprea Therapeutics, Inc.. Currently has a direct ownership of 4,401 shares of APRE, which is worth approximately $16,811. The most recent transaction as insider was on Jun 20, 2024, when has been sold 1,045 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 4.4K
31.14% 3M change
92.3% 12M change
Total Value Held $16,811

Rifat Pamukcu Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 20 2024
BUY
Grant, award, or other acquisition
-
1,045 Added 19.19%
4,401 Common Stock
Aug 23 2023
BUY
Grant, award, or other acquisition
-
500 Added 12.97%
3,356 Common Stock
Aug 23 2022
BUY
Conversion of derivative security
-
49,280 Added 46.31%
57,142 Common Stock
Jul 28 2022
BUY
Grant, award, or other acquisition
-
5,995 Added 43.26%
7,862 Common Stock
RP

Rifat Pamukcu

Director
Boston, MA

Track Institutional and Insider Activities on APRE

Follow Aprea Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APRE shares.

Notify only if

Insider Trading

Get notified when an Aprea Therapeutics, Inc. insider buys or sells APRE shares.

Notify only if

News

Receive news related to Aprea Therapeutics, Inc.

Track Activities on APRE